Blue Trust Inc. Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Blue Trust Inc. increased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 83.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,868 shares of the specialty pharmaceutical company’s stock after acquiring an additional 851 shares during the period. Blue Trust Inc.’s holdings in Jazz Pharmaceuticals were worth $230,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Creative Planning lifted its stake in shares of Jazz Pharmaceuticals by 21.7% in the second quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company’s stock valued at $408,000 after purchasing an additional 680 shares during the period. Sanctuary Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $213,000. SG Americas Securities LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $752,000. GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 121 shares during the period. Finally, Wedmont Private Capital increased its stake in Jazz Pharmaceuticals by 11.4% in the 3rd quarter. Wedmont Private Capital now owns 4,972 shares of the specialty pharmaceutical company’s stock valued at $540,000 after purchasing an additional 507 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity

In related news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,253 shares of company stock valued at $890,594 in the last 90 days. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $121.97 on Tuesday. The stock has a fifty day moving average price of $122.69 and a 200 day moving average price of $116.10. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.17. The firm has a market capitalization of $7.37 billion, a P/E ratio of 17.18, a PEG ratio of 0.90 and a beta of 0.56. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Analyst Ratings Changes

Several research firms have weighed in on JAZZ. TD Cowen lowered their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Finally, Piper Sandler reissued an “overweight” rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $177.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.